Metabolic and additional vascular effects of thiazolidinediones.
about
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a reviewInfluence of diabetes mellitus on heart failure risk and outcomeNetwork-based approaches in drug discovery and early developmentPPAR-γ -- a possible drug target for complicated pregnanciesPPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertaintyEffect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.Coronary microvascular dysfunction in diabetes mellitus: A reviewDiabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI studyPioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulinNonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trialPharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome.Identification of a novel selective agonist of PPARγ with no promotion of adipogenesis and less inhibition of osteoblastogenesis.Antiallergic Function of KR62980, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in a Mouse Allergic Rhinitis Model.Metabolic syndrome in peritoneal dialysis patients.Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease.Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality.Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?Slowing cardiovascular disease progression in African-American patients: diabetes management.Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.Acute rosiglitazone treatment during reperfusion after hyperglycemic stroke is neuroprotective not vascular protectiveObesity drugs and their targets: correlation of mouse knockout phenotypes with drug effects in vivo.Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial.Significance of anti-inflammatory effects of PPARgamma agonists?Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.Comparative safety of newer oral antidiabetic drugs.The vascular endothelium in diabetes--a therapeutic target?Hypertension in metabolic syndrome: vascular pathophysiology.PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseasesRapid pain modulation with nuclear receptor ligands.PPARγ activation blocks development and reduces established neuropathic pain in rats.Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.The prince and the pauper. A tale of anticancer targeted agents.Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF ratsRosiglitazone modulates pigeon atherosclerotic lipid accumulation and gene expression in vitro.
P2860
Q24561401-93A28CCF-4825-4CA0-AFA6-DC4DC7594C54Q24800363-642B9E79-BD8D-4CA4-BF54-D88FCD7AAAD6Q26827940-B20C5C57-B5EB-4809-AFB6-25DBDED1B9FAQ26863678-849FB290-F991-48A5-BB67-AED0E637EDEEQ27024799-DC65DB2D-A24B-4AC6-A29A-E9BEEB880D5AQ34399438-DA0F020B-5EEF-47E9-A52E-069C19043F04Q34427072-74793DD5-1537-46BE-B77C-20C589574395Q34540104-21C0EFAD-1E9F-4BFE-A6AF-12963A74BB6BQ34620604-43EAC548-A867-4EDF-9B70-FCF472D08C2BQ34659408-1149CC1E-2F73-4320-8A87-7D37B06C7D7AQ34721973-C56A1734-E2B5-4A4C-8CF5-5F3FAB29E8FCQ35039274-F88A56A1-2E96-42AC-BCB9-837439DD8AA0Q35207615-97EB79FE-63C2-4E2D-91D5-E0821F54835DQ35237706-95E99D72-2B2D-4483-8F0B-72F7F29B1CC8Q35420583-3039B3F3-2F6C-4DBE-A069-A920FFB62DCBQ35573741-21ED6936-4466-4E16-B512-B5D84EF68748Q35588998-46DBCA75-CBE4-4849-8376-C4C4E8C8F919Q35629015-7E338BEA-02BE-4858-8F50-EB18F838965AQ35688221-E3275C56-4192-4D4F-B2DB-5236A5B1D2B4Q35741754-75D1BA39-B4A2-43EB-B070-63EE574A037AQ35803453-C1723865-9FCF-41E6-BA3F-BB4A761E38B4Q36187022-42877567-2EE4-4B92-8E31-D25AF0D32552Q36359324-88763970-F36A-445A-9148-ED6239DD3000Q36377258-34765E7B-4865-4C2D-88A0-9FFA53C01B2AQ36390892-690B4DF4-61D9-482C-BBBE-0A8998375AA4Q36407383-FEC22F24-E814-478F-AF47-A4685CD70B38Q36474275-E5AC6C94-AF39-4214-BD01-DBD8EA680B90Q36540016-82DF37F0-7C10-4858-A5F6-B5C962BD8A84Q36569766-7ABE7A63-4738-45C1-8386-FE1CC3EFF0C3Q36624990-B9DC9432-7FAB-43DC-8D70-1A224339A00FQ36673550-30CEE876-F821-4569-A488-C3FC141BDC77Q36737819-983CE694-BA1D-4F91-BA94-460D98144A53Q36787677-40D330D3-B8AD-4AD3-A848-832BB38452D0Q36918509-ABD2FBA9-B8A3-44A8-96BE-90E73CBA07F9Q36964412-CF5ABC29-4F04-4037-B1FC-E6F1DFB39B2FQ36964445-A5947A40-63D7-43C1-84A8-1E5DF29945F3Q36966063-03F44A77-0B22-48CF-884E-20E3CB381889Q37042365-B16E5B32-44D7-417B-905E-579037927870Q37065532-2F97C389-674D-40BE-B923-DC651928CB68Q37183777-EAC3676A-511C-4FED-9636-98C8B9F8AB12
P2860
Metabolic and additional vascular effects of thiazolidinediones.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Metabolic and additional vascular effects of thiazolidinediones.
@ast
Metabolic and additional vascular effects of thiazolidinediones.
@en
Metabolic and additional vascular effects of thiazolidinediones.
@nl
type
label
Metabolic and additional vascular effects of thiazolidinediones.
@ast
Metabolic and additional vascular effects of thiazolidinediones.
@en
Metabolic and additional vascular effects of thiazolidinediones.
@nl
prefLabel
Metabolic and additional vascular effects of thiazolidinediones.
@ast
Metabolic and additional vascular effects of thiazolidinediones.
@en
Metabolic and additional vascular effects of thiazolidinediones.
@nl
P2093
P1433
P1476
Metabolic and additional vascular effects of thiazolidinediones
@en
P2093
Eelco J P de Koning
Fabrice M A C Martens
Jacinthe Lemay
P304
P356
10.2165/00003495-200262100-00004
P577
2002-01-01T00:00:00Z
P5875
P6179
1012559787